The estimated Net Worth of Leif E Pedersen is at least 5.28 百万$ dollars as of 9 September 2024. Mr Pedersen owns over 51,224 units of Certara stock worth over 1,094,750$ and over the last 4 years he sold CERT stock worth over 3,889,901$. In addition, he makes 295,397$ as Pres of Software at Certara.
Mr has made over 6 trades of the Certara stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 51,224 units of CERT stock worth 578,319$ on 9 September 2024.
The largest trade he's ever made was selling 51,224 units of Certara stock on 9 September 2024 worth over 578,319$. On average, Mr trades about 25,560 units every 122 days since 2021. As of 9 September 2024 he still owns at least 99,704 units of Certara stock.
You can see the complete history of Mr Pedersen stock trades at the bottom of the page.
Leif E. Pedersen is the Pres of Software at Certara.
As the Pres of Software of Certara, the total compensation of Mr Pedersen at Certara is 295,397$. There are 2 executives at Certara getting paid more, with Dr. William F. Feehery Ph.D. having the highest compensation of 1,387,564$.
Mr Pedersen is 57, he's been the Pres of Software of Certara since . There are no older and 5 younger executives at Certara.
Leif's mailing address filed with the SEC is C/O CERRTARA, INC., 4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR, PA, 19087.
Over the last 5 years, insiders at Certara have traded over 2,048,278,243$ worth of Certara stock and bought 97,245 units worth 1,908,085$ . The most active insiders traders include Avatar Parent L.P.Eqt Avata...、James E Iii Cashman、Mason P Slaine. On average, Certara executives and independent directors trade stock every 14 days with the average trade being worth of 7,828,136$. The most recent stock trade was executed by Leif E Pedersen on 9 September 2024, trading 51,224 units of CERT stock currently worth 578,319$.
Certara Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinincal and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software and technology to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, and Australia. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
Certara executives and other stock owners filed with the SEC include: